Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)
Syros Pharmaceuticals Reports SELECT-AML-1 Trial Outcomes
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
Sector Update: Health Care Stocks Rise Late Afternoon
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
Top Midday Decliners
S&P 500 Gains 1%; Home Depot Earnings Top Views
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Syros Pharmaceuticals SYRS Phase 2 Data; Biora Therapeutics BIOR Funding
Syros Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Syros Pharmaceuticals Price Target Cut to $4.00/Share From $12.00 by JMP Securities
Express News | Syros Pharmaceuticals Shares Down 62.5% at $1.88 Premarket After Interim Data Shows Co's Rare Blood Cancer Therapy Unlikely to Suceed in Study
Top Premarket Decliners
TD Cowen Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating
TD Cowen analyst Phil Nadeau maintains $Syros Pharmaceuticals(SYRS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.0% and a total average return of 4.8% over
HC Wainwright & Co. Maintains Buy on Syros Pharmaceuticals, Lowers Price Target to $6
Piper Sandler Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)